GlassScriptPhysician profile
Cory J Lemoine
NPI 1760836597
$3,278.12
in general payments reported to CMS, 2019-2025
28 companies · $860 in 2025
The $860 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.76 · 2020: $146 · 2021: $435 · 2022: $368 · 2023: $726 · 2024: $711 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,297.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $618.71 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $452.26 | 2020-2025 | |
| Glaxosmithkline, LLC. | $290.32 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $250.40 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $195.24 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $178.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $164.09 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $131.15 | 2023-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $130.97 | 2022-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $125.58 | 2021-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.80 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $95.77 | 2021-2025 | |
| Gilead Sciences, INC. | $88.47 | 2025 | |
| Abbott Laboratories | $71.45 | 2023-2025 | Freestyle Libre 3 |
| Corium, LLC | $70.41 | 2025 | Azstarys |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $36.87 | 2024 | |
| Currax Pharmaceuticals LLC | $33.52 | 2024-2025 | Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.90 | 2021-2022 | |
| Neos Therapeutics, LP | $30.41 | 2024 | Adzenys Xr-Odt |
| Novartis Pharmaceuticals Corporation | $30.30 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $22.54 | 2025 | Camzyos |
| Esperion Therapeutics, INC. | $20.84 | 2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.23 | 2024 | Caplyta |
| Phathom Pharmaceuticals, INC. | $19.00 | 2025 | Voquezna |
| Dexcom, INC. | $18.21 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $16.74 | 2023 | |
| Merck Sharp & Dohme LLC | $16.33 | 2025 | Capvaxive, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $14.30 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Lemoine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.